Please login to the form below

Not currently logged in


This page shows the latest ISIS-APOCIII Rx news and features for those working in and with pharma, biotech and healthcare.

Biogen Idec gets exclusive access to Isis' neurology R&D

Biogen Idec gets exclusive access to Isis' neurology R&D

In early 2012, Biogen Idec tapped into Isis' antisense technology to try to develop a new drug called ISIS-SMN Rx to treat spinal muscular atrophy. ... Meanwhile, Isis has also just reported encouraging data from a phase II trial ISIS-APOCIII Rx for

Latest news

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    ISIS-APOCIII Rx can cause triglycerides to drop 75 per cent. Antisense specialist Isis Pharmaceuticals shares leapt this week after the company reported positive data with its triglyceride-lowering drug candidate. ... ISIS-APOCIII Rx achieved a

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...